Repligen Corporation $RGEN Shares Acquired by Bamco Inc. NY

Bamco Inc. NY grew its stake in Repligen Corporation (NASDAQ:RGEN) by 39.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 381,678 shares of the biotechnology company’s stock after buying an additional 107,235 shares during the period. Bamco Inc. NY owned 0.68% of Repligen worth $51,019,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. CWM LLC increased its position in shares of Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 135 shares during the period. Johnson Financial Group Inc. purchased a new stake in Repligen during the 3rd quarter valued at about $65,000. Trust Co. of Vermont purchased a new stake in Repligen during the 3rd quarter valued at about $67,000. Wilmington Savings Fund Society FSB increased its holdings in shares of Repligen by 2,750.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 495 shares during the period. Finally, Hantz Financial Services Inc. increased its holdings in shares of Repligen by 92.8% in the third quarter. Hantz Financial Services Inc. now owns 586 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 282 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Up 0.4%

Shares of NASDAQ:RGEN opened at $114.20 on Monday. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $175.77. The business has a 50 day moving average of $145.43 and a two-hundred day moving average of $147.05. The company has a market capitalization of $6.43 billion, a PE ratio of 134.35, a PEG ratio of 2.23 and a beta of 1.15.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. During the same quarter last year, the company earned $0.44 EPS. The business’s revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on RGEN shares. Wells Fargo & Company decreased their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. KeyCorp restated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. Finally, Barclays cut their price objective on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.